Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations – Yahoo Finance
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations Yahoo FinanceNovo shares slide as drugmaker lays out post-Wegovy growth…
Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent…